Home›Oncology› HR-positive HER2-low breast cancer accounts for 60% of cases; deruxtecan reshapes treatment
HR-positive HER2-low breast cancer accounts for 60% of cases; deruxtecan reshapes treatmentNew drug class reshapes treatment for common breast cancer type
Frontiers in MedicinePublished July 18, 2026DOI ↗Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider molecular typing to guide treatment in HR-positive HER2-low breast cancer, with endocrine therapy and CDK4/6 inhibitors as standard.
This systematic review focuses on HR-positive HER2-low-expressing breast cancer, a subtype that accounts for nearly 60% of overall breast cancer incidence. The review synthesizes current evidence on diagnosis, dynamic monitoring, and treatment approaches, emphasizing the transition to individualized precise therapy guided by molecular typing.
Key findings highlight endocrine therapy as a cornerstone of treatment and CDK4/6 inhibitors as standard first-line therapy. The review also notes that antibody-drug conjugates, specifically deruxtecan, have significantly improved patient prognosis and reshaped the treatment landscape, though specific statistical data or trial results for this claim were not provided in the review.
The review underscores the importance of dynamic monitoring capabilities and accurate diagnosis in managing this patient population. However, limitations include a lack of reported sample sizes, follow-up durations, and specific effect sizes for key outcomes. Safety data, including adverse events and tolerability, were not reported.
In practice, this review supports the use of molecular typing to guide treatment decisions in HR-positive HER2-low breast cancer, with endocrine therapy and CDK4/6 inhibitors remaining central. The role of deruxtecan appears promising but requires further quantitative evidence to confirm its impact.
How this fits prior evidence
This systematic review extends prior coverage by focusing specifically on HR-positive HER2-low breast cancer, a subtype not addressed in earlier reports. Prior findings on neoadjuvant chemotherapy with angiogenesis inhibitors in triple-negative breast cancer and tamoxifen in PR-positive postmenopausal breast cancer addressed different subtypes. The review's emphasis on molecular typing aligns with the multi-method approach that increased detection of nonadherent patients, highlighting the trend toward personalized care. However, unlike prior reports with specific effect sizes (e.g., tamoxifen HR 0.37), this review lacks quantitative data for deruxtecan's benefit.
If you or someone you love has been diagnosed with breast cancer, the type matters. A new review reveals that nearly 60% of all breast cancers are a specific type: HR-positive HER2-low. That's a huge number of people who may benefit from a newer approach.
For years, treatment for HR-positive breast cancer has relied on endocrine therapy and CDK4/6 inhibitors. Those remain the standard first-line options. But the review highlights a new class of drugs called antibody-drug conjugates, specifically one called deruxtecan. These drugs have significantly improved patient prognosis and reshaped the treatment landscape.
The review emphasizes that treatment is moving toward more personalized care based on molecular typing. That means doctors can better match the therapy to the tumor's specific characteristics. However, the review does not provide specific numbers on how much deruxtecan improves outcomes, so the exact benefit isn't clear from this analysis alone.
What this means for you:
Nearly 60% of breast cancers are HR-positive HER2-low, and new drugs are improving outcomes.
Common questions
What is HR-positive HER2-low breast cancer?
It's a type of breast cancer that has hormone receptors (HR-positive) and low levels of a protein called HER2. This type makes up nearly 60% of all breast cancers, according to a recent review.
How is HR-positive HER2-low breast cancer treated?
Standard first-line treatment includes endocrine therapy and CDK4/6 inhibitors. A newer option is antibody-drug conjugates like deruxtecan, which have significantly improved prognosis for these patients.
What are antibody-drug conjugates?
They are a type of targeted cancer therapy that combines an antibody with a chemotherapy drug. The antibody seeks out cancer cells, delivering the drug directly to them. Deruxtecan is one example used for HER2-low breast cancer.
Is deruxtecan a cure for breast cancer?
The review says deruxtecan has significantly improved patient prognosis and reshaped treatment, but it does not provide specific cure rates. It's an important advance, but more research is needed to understand long-term outcomes.
HR-positive HER2-low-expressing breast cancer is a unique subtype that has been refined from the traditional HER2 binary classification system in recent years, accounting for nearly 60% of the overall incidence of breast cancer. It has significant value for precise diagnosis and treatment research. This review systematically elaborates on the epidemiological characteristics, biological basis, diagnostic technology progress, and treatment strategy evolution of this subtype. HR-positive HER2-low-expressing breast cancer is characterized by the dominance of the estrogen receptor pathway and the core molecular feature of the intersection of HER2 low-expression signals. Its diagnosis requires a balance between the fundamental role of endocrine therapy and the precise screening of anti-HER2 targeted therapy. In terms of diagnosis, the initial screening by immunohistochemistry combined with fluorescence in situ hybridization has formed a standardized process. The integration of digital pathology, next-generation sequencing, and circulating tumor DNA in liquid biopsy technologies has effectively improved diagnostic accuracy and dynamic monitoring capabilities. In terms of treatment, endocrine therapy is the cornerstone, and the CDK4/6 inhibitor combination regimen is the standard for advanced first-line treatment. Antibody-drug conjugates, especially deruxtecan, have significantly improved patient prognosis and reshaped the treatment landscape. In summary, HR-positive HER2-low-expressing breast cancer has entered the era of individualized precise treatment guided by molecular typing. In the future, further exploration of new biomarkers, optimization of combination therapy strategies, and high-quality clinical research are needed to continuously improve patient survival outcomes.
